Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that remains incurable, despite decades of basic and clinical research. Key stakeholders—including the US National ...
After raising questions surrounding dosing levels, the FDA has freed Amylyx’s early-stage amyotrophic lateral sclerosis (ALS) ...
When a renowned Israeli TV journalist lost his ability to speak clearly because of ALS, he thought his career might be over.
Eli Lilly partnership aims to identify new treatments for ALS based on antibodies from people with very slow disease ...
Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for ...
The company in March said its ALS drug Relyvrio had failed a late-stage clinical trial, and the stock has sunk more than 78% over the past year. Amylyx pulled Relyvrio from the market, cut its ...
Zydus Lifesciences announced that Usnoflast, a treatment for amyotrophic lateral sclerosis (ALS), has received Orphan Drug Designation from the US FDA. This designation supports the development of ...
A New Bedford man was sentenced to prison for conspiring to steal and then depositing over $450,000 from a U.S. Marine ...
A diagnosis of amyotrophic lateral sclerosis, or ALS, is difficult for anyone to hear. But that was especially the case for ...
Joseph Smith, 71, was sentenced to 23 months in prison to be followed by two years of supervised release. He was charged with ...
Zydus’ Usnoflast receives US FDA orphan drug designation to treat amyotrophic lateral sclerosis: Our Bureau, Mumbai Thursday, January 23, 2025, 12:15 Hrs [IST] Zydus, a leading, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback